Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02000089 · ClinicalTrials.gov registry record · Phase 3

The Cancer of the Pancreas Screening-5 CAPS5)Study

A Phase 3 study of Pancreas Cancer and Lynch Syndrome, sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 3
Development phase
9,000
Enrollment target
9
Study locations

NCT02000089 is a Phase 3 study of Pancreas Cancer and Lynch Syndrome that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 9,000 participants, above the 741-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (1115% higher). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02000089, a Phase 3 study of Pancreas Cancer and Lynch Syndrome, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 3
Development phase
9,000 participants
Enrollment target
9
Study locations

Study Summary

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Conditions Studied

Pancreas Cancer Lynch Syndrome Peutz-Jeghers Syndrome (PJS) Gene Mutation Germline Mutation Carrier

Interventions

  • DRUG Secretin
  • DIAGNOSTIC_TEST MRI
  • OTHER Tumor marker gene test with CA19-9

Study Locations (9)

New York

  • NYU Langone Medical Center - New York
  • Columbia University Medical Center - New York

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • University of Pittsburgh - Pittsburgh

Connecticut

  • Yale University - New Haven

Maryland

  • Johns Hopkins Hospital - Baltimore

Massachusetts

  • Dana Farber Cancer Center, Harvard University - Boston

Michigan

  • University of Michigan - Ann Arbor

Ohio

  • Case Comprehensive Cancer Center, Case Western Medical Reserve - Cleveland

Trial Details

FieldValue
Enrollment Target 9,000 participants
Start Date 2014-01-06
Est. Completion 2029-06
Phase Phase 3

Sponsor

Johns Hopkins University

1,448 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02000089

The ClinicalTrials.gov registry entry for NCT02000089 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 9,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 741-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (1115% higher). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Pancreas Cancer appearing as the primary indexed condition, and to 3 interventions - of which Secretin is the first listed.

NCT02000089 reports 9 study locations spanning 7 distinct geographic areas - top geographies include New York, Pennsylvania, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02000089 about?

NCT02000089 is a clinical study titled "The Cancer of the Pancreas Screening-5 CAPS5)Study". Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

What is the current status of trial NCT02000089?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 9,000 participants. The study started on 2014-01-06. Estimated completion is 2029-06.

What conditions does trial NCT02000089 study?

This clinical trial studies the following conditions: Pancreas Cancer, Lynch Syndrome, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier.

What interventions are being tested in trial NCT02000089?

The interventions under investigation include: Secretin (DRUG), MRI (DIAGNOSTIC_TEST), Tumor marker gene test with CA19-9 (OTHER).

Who is sponsoring clinical trial NCT02000089?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02000089 being conducted?

This trial has 9 study locations across Connecticut, Maryland, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreas Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreas Cancer

All registered trials for this condition

Lynch Syndrome

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.